Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

SGLT2 inhibitors in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials balancing their risks and benefits
Elisa Marilly, Judith Cottin, Natalia Cabrera, et al.
Diabetologia (2022) Vol. 65, Iss. 12, pp. 2000-2010
Open Access | Times Cited: 63

Showing 1-25 of 63 citing articles:

SGLT2 inhibitors: role in protective reprogramming of cardiac nutrient transport and metabolism
Milton Packer
Nature Reviews Cardiology (2023) Vol. 20, Iss. 7, pp. 443-462
Open Access | Times Cited: 102
Advances in Research on Type 2 Diabetes Mellitus Targets and Therapeutic Agents
Jingqian Su, Yingsheng Luo, Shan Hu, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 17, pp. 13381-13381
Open Access | Times Cited: 46
Hyperglycemic Crises in Adults With Diabetes: A Consensus Report
Guillermo E. Umpierrez, Georgia M. Davis, Nuha A. ElSayed, et al.
Diabetes Care (2024) Vol. 47, Iss. 8, pp. 1257-1275
Open Access | Times Cited: 46
Hyperglycaemic crises in adults with diabetes: a consensus report
Guillermo E. Umpierrez, Georgia M. Davis, Nuha A. ElSayed, et al.
Diabetologia (2024) Vol. 67, Iss. 8, pp. 1455-1479
Open Access | Times Cited: 30
Effectiveness and safety of the combination of sodium–glucose transport protein 2 inhibitors and glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes mellitus: a systematic review and meta-analysis of observational studies
Aftab Ahmad, Hani Sabbour
Cardiovascular Diabetology (2024) Vol. 23, Iss. 1
Open Access | Times Cited: 11
Beta-Hydroxybutyrate Levels and Risk of Diabetic Ketoacidosis in Adults with Type 1 Diabetes Treated with Sotagliflozin
Schafer Boeder, Michael J. Davies, Janet B. McGill, et al.
Diabetes Technology & Therapeutics (2024) Vol. 26, Iss. 9, pp. 618-625
Closed Access | Times Cited: 9
Empagliflozin ameliorates renal and metabolic derangements in obese type 2 diabetic mice by blocking advanced glycation end product–receptor axis
Takanori Matsui, Ami Sotokawauchi, Yuri Nishino, et al.
Molecular Medicine (2025) Vol. 31, Iss. 1
Open Access | Times Cited: 1
SGLT2 Inhibitors vs. GLP-1 Agonists to Treat the Heart, the Kidneys and the Brain
Bartosz Rolek, Mateusz Haber, Magdalena Gajewska, et al.
Journal of Cardiovascular Development and Disease (2023) Vol. 10, Iss. 8, pp. 322-322
Open Access | Times Cited: 20
Systemic and organ-specific anti-inflammatory effects of sodium-glucose cotransporter-2 inhibitors
Mona Mashayekhi, Bilgunay Ilkin Safa, Matthew S.C. Gonzalez, et al.
Trends in Endocrinology and Metabolism (2024) Vol. 35, Iss. 5, pp. 425-438
Closed Access | Times Cited: 8
Use of sodium‐glucose cotransporter‐2 inhibitors in France: Analysis of French nationwide health insurance database
Sibylle de Germay, Élodie Pambrun, Alexandre Pariente, et al.
Diabetes Obesity and Metabolism (2024) Vol. 26, Iss. 5, pp. 1678-1686
Open Access | Times Cited: 7
Ipragliflozin and sitagliptin differentially affect lipid and apolipoprotein profiles in type 2 diabetes: the SUCRE study
Mototsugu Nagao, Junichi Sasaki, Kyoko Tanimura‐Inagaki, et al.
Cardiovascular Diabetology (2024) Vol. 23, Iss. 1
Open Access | Times Cited: 6
Comparative effects of glucagon-like peptide-1 receptor agonists and sodium-glucose co-transporter-2 inhibitors on heart failure with preserved ejection fraction in diabetic patients: a meta-analysis
Arif Albulushi, Desmond Boakye Tanoh, Ahmed Almustafa, et al.
Cardiovascular Diabetology (2024) Vol. 23, Iss. 1
Open Access | Times Cited: 6
Development of canagliflozin nanocrystals sublingual tablets in the presence of sodium caprate permeability enhancer: formulation optimization, characterization, in-vitro , in silico , and in-vivo study
Sammar Fathy Elhabal, Mohamed A. El-Nabarawi, Nashwa Abdelaal, et al.
Drug Delivery (2023) Vol. 30, Iss. 1
Open Access | Times Cited: 15
Genito-urinary infectious adverse events related to sodium glucose cotransporter-2 inhibitors: a network meta-analysis and meta-regression
Kannan Sridharan, Gowri Sivaramakrishnan
Expert Review of Clinical Pharmacology (2024) Vol. 17, Iss. 5-6, pp. 515-524
Closed Access | Times Cited: 5
The effect of SGLT2 inhibition on prostate cancer: Mendelian randomization and observational analysis using electronic healthcare and cohort data
Jie Zheng, Jieli Lu, Jiying Qi, et al.
Cell Reports Medicine (2024) Vol. 5, Iss. 8, pp. 101688-101688
Open Access | Times Cited: 5
Early combination therapy with SGLT2i and GLP‐1 RA or dual GIP/GLP‐1 RA in type 2 diabetes
Catarina Vale, Inês Mariana Lourenço, Gabriela Jordan, et al.
Diabetes Obesity and Metabolism (2024) Vol. 27, Iss. 2, pp. 468-481
Closed Access | Times Cited: 4
SGLT-2 inhibitors and diabetic ketoacidosis
F. Agozzino, Teresa Falco, Antonio Villa
Internal and Emergency Medicine (2025)
Closed Access
Kidney outcomes with SGLT2 inhibitors in patients with diabetes and an insulin‐deficient phenotype: A real world analysis
Anat Tsur, Avivit Cahn, Lior Hanoch, et al.
Diabetes Obesity and Metabolism (2025)
Open Access
Achievements in the Pathophysiology and Treatment of Insulin Resistance: Every Step Matters
George Dimitriadis
Nutrients (2025) Vol. 17, Iss. 7, pp. 1223-1223
Open Access
Novel Therapeutic Approaches for Treatment of Diabetic Retinopathy and Age-Related Macular Degeneration
Deokho Lee, Soo Jin Kim, Junyeop Lee
Vision (2025) Vol. 9, Iss. 2, pp. 35-35
Open Access
Safety of sodium-glucose transporter 2 (SGLT-2) inhibitors in patients with type 2 diabetes: a meta-analysis of cohort studies
Chun Xing Li, Tian Tian Liu, Qian Zhang, et al.
Frontiers in Pharmacology (2023) Vol. 14
Open Access | Times Cited: 10
SGLT2 Inhibitor Use and Risk of Breast Cancer Among Adult Women with Type 2 Diabetes
Fengge Wang, Michael Hendryx, Nianjun Liu, et al.
Drug Safety (2023) Vol. 47, Iss. 2, pp. 125-133
Closed Access | Times Cited: 10
SGLT2 inhibitor improves the prognosis of patients with coronary heart disease and prevents in-stent restenosis
Qing Zhang, Zhiwen Deng, Tudi Li, et al.
Frontiers in Cardiovascular Medicine (2024) Vol. 10
Open Access | Times Cited: 3
Are We Ready for Expanding the Use of Sodium–Glucose Cotransporter-2 Inhibitors in Patients With Acute Myocardial Infarction?
Paschalis Karakasis, Dimitrios Patoulias, George Giannakoulas, et al.
Journal of Cardiovascular Pharmacology (2024) Vol. 84, Iss. 1, pp. 26-28
Open Access | Times Cited: 3
Empagliflozin alters lipid metabolism in the myocardium and liver in a prediabetes model with severe dyslipidemia
Denisa Miklánková, Irena Marková, Martina Hüttl, et al.
Frontiers in Pharmacology (2024) Vol. 15
Open Access | Times Cited: 3
Page 1 - Next Page

Scroll to top